Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy

Area of Science:

• Oncology
• Cancer Biology
• Tumor Microenvironment

Background:

• Impaired delivery of antineoplastic agents to solid tumors is linked to the tumor microenvironment.
• Vascular endothelial growth factor (VEGF) drives aberrant tumor vasculature, characterized by chaotic, leaky vessels, high interstitial fluid pressure, and poor blood flow.

Purpose of the Study:

• To review how VEGF influences tumor vasculature and the tumor microenvironment.
• To examine the impact of the tumor microenvironment on antineoplastic agent delivery.
• To explore the potential of combining anti-VEGF therapy with cytotoxic agents to enhance treatment efficacy.

Main Methods:

• Review of existing literature on VEGF, tumor vasculature, and the tumor microenvironment.
• Analysis of the mechanisms by which aberrant vasculature impedes drug delivery.
• Evaluation of the rationale for combining anti-VEGF therapy with chemotherapy.

Main Results:

• VEGF is a key factor in developing abnormal tumor vasculature with high interstitial fluid pressure and inefficient blood flow.
• This abnormal vasculature creates a tumor microenvironment that hinders the delivery of chemotherapy drugs.
• Reducing interstitial fluid pressure through anti-VEGF therapy is hypothesized to improve blood flow and drug delivery.

Conclusions:

• Targeting VEGF may normalize tumor vasculature, thereby improving drug delivery to cancer cells.
• Combination therapy with anti-VEGF agents and cytotoxic drugs holds promise for maximizing antineoplastic treatment efficacy.
• Understanding the tumor microenvironment is crucial for optimizing cancer therapy strategies.